Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19. 

Biotechnology

Valneva

Thomas Lingelbach

Vincent Dequenne

Petra Pesendorfer

Franck Grimaud

Dipal Patel

Peter Bühler

Juan Carlos Jaramillo

Frederic Jacotot

The board of directors at Valneva has a history of experience with member of SAB at Vaxxinity, member of SAB at 康希诺生物股份公司 CanSino Biologics Inc., and member of SAB at Clover Biopharmaceuticals. The board also has a history of education with Harvard Medical School, Vaccinology, University of Delaware, Psychology, and ISIC Mons - Belgium, Electromechanical Engineering.

Board of Directors

Leadership Team

CEO and Executive Team

Board of Directors

About

Team members

Other teams at Valneva

Leadership Team

CEO and Executive Team